Sorted By:


Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box

PhRMA  |  Blog Post

Ubl joined Squawk Box this morning to put medicine costs and spending in context, the biopharmaceutical supply chain and policy solutions to address cost concerns and continue U.S. leadership in medical innovation.

Medicare Monday: Stakeholders raise concern with MedPAC’s proposed changes to drug purchasing program

PhRMA  |  Blog Post

The Community Oncology Alliance points out, “There are numerous problems with the Part B Drug Value Program (DVP) outlined in the MedPAC draft recommendations [… ] the idea of creating a formulary to artificially induce competition in price negotiations, administered by a third party PBM-type entity, is simply reckless.

Ebola: The Biopharm Industry Committed to Advancements

PhRMA  |  Report

Researchers around the world, from both the public and private sectors, are increasingly working collaboratively to develop new ways to prevent the spread of Ebola and treat patients who have contracted the virus. The research and development process for new medicines is a lengthy, challenging an...

Medicare Monday: A closer look at Part B spending

PhRMA  |  Blog Post

That’s according to MedPAC and the Medicare Trustees report.


PhRMA  |  From PhRMA

Scientific discovery is key to developing new treatments to improve patient health and save lives. America’s biopharmaceutical researchers are tireless in the pursuit of new treatments and cures. Thanks to the innovative medicines they've developed, patients al...

Medicare Monday: What they are saying about MedPAC’s Part B recommendations

PhRMA  |  Blog Post

If implemented, these recommendations will cause the complete opposite of their intent, fueling more increases in Part B costs for Medicare and beneficiaries.” – Jeff Vacirca, M.D., president of Community Oncology Alliance Patient Access to Community Treatment Coalition: “Reducing payments for Part B medicines would create further difficulties for providers, especially those in small practices and rural settings, to provide affordable medications to patients in critical need.

No Stone Unturned in Mental Health Research

PhRMA  |  Video

Doug Williamson, Chief Medical Officer at Lundbeck and Dr.

Enforcing unmet trade obligations protects U.S. innovation

PhRMA  |  Blog Post

Many countries, including China, Brazil, Russia and India, have failed to comply with their trade agreements to protect RDP.

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

PhRMA  |  Blog Post

America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property protections, public sector investments in education and basic sciences, and a reliable rule of law.

Las Compañías Biofarmacéuticas de Estados Unidos Lanzan una Innovadora Iniciativa Anunciando la Nueva Era de la Medicina

PhRMA  |  Press Release

Desde el año 2000, las empresas miembros de PhRMA han invertido más de medio trillón de dólares en la búsqueda de nuevos tratamientos y curas, incluyendo un estimado de $58.8 mil millones en el año 2015 por sí solo.

America’s biopharmaceutical industry is central to diverse R&D ecosystem

PhRMA  |  Video

Eli Lilly and Company’s chief medical officer, Dr.

From Discovery Through Delivery, Policies Must Foster Continued Innovation and Patient Access to Personalized Medicines

Chartpack  |  From Our Network

At a time when the scientific promise is greater than ever, thoughtful policies are necessary to accelerate advances in targeted therapy for patients. ...


PhRMA  |  Video

Medical advancements, like immunotherapy, give patients the ability to fight cancer with everything they have – including their own cells, so witness the destruction of a cancer cell.

Nuevos Informes Destacan el Aumento de la Competencia Global en I + D Biofarmacéutica, Planteando Desafíos Significativos para la Futura Posición de Estados Unidos

PhRMA  |  Press Release

Desde el año 2000, las empresas miembros de PhRMA han invertido más de medio trillón de dólares en la búsqueda de nuevos tratamientos y curas, incluyendo un estimado de $58.8 mil millones sólo en el año 2015.

Illegal trade barriers discriminate against U.S. innovators

PhRMA  |  Blog Post

Unfortunately, U.S. trade partners – including Argentina, China, India, Indonesia, Russia, Turkey and Vietnam – are resorting to “localization barriers” which unfairly discriminate against U.S. products.

In the OECD other health care services will be ten times prescription medicine spending growth over next decade

PhRMA  |  Blog Post

In the midst of this medical progress, other health care expenditures such as inpatient care, long-term care and administration, have grown much faster than prescription medicine expenditures.

Rare Disease Day: Accelerating innovation for patients in need

PhRMA  |  Blog Post

Although a rare disease is generally defined as affecting fewer than 200,000 people in the United States, research suggests that the median population size for rare diseases is actually fewer than 10,000 patients.

Part B

PhRMA  |  From PhRMA

These medicines represent some very significant medical advances, including breakthroughs in cancer, rheumatoid arthritis and autoimmune conditions.

ICYMI: New era of medicine initiative kicks off in Boston

PhRMA  |  Blog Post

The event, convened by The Atlantic, titled, “Through the Microscope: Examining Modern Medicine,” explored the transformation of patient care and the science that has revolutionized medical breakthroughs, new treatments and technologies, as well as the investments needed for future innovation.

VIDEO: PhRMA CEO joins Fox Business anchor Neil Cavuto to discuss personal connection to value of innovation and White House meeting

PhRMA  |  Blog Post

FOX Business anchor Neil Cavuto on his personal connection to the value of medical technology with his son’s type 1 diabetes diagnosis, the industry’s meeting with President Donald J.

Helping those affected by the 2017 hurricane season

PhRMA  |  Blog Post

They are also working to implement business continuity plans to ensure patients and medical professionals have continued access to medical devices and pharmaceutical products.

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

PhRMA  |  Blog Post

The launch of GOBOLDLY, our new national, multi-year initiative brings those bold, life-changing medical discoveries to the forefront.

Examining the brain in The New Era of Medicine

PhRMA  |  Blog Post

Eric Siemers, senior medical director, Alzheimer's Global Development Team at Eli Lilly and Co., who currently directs late stage clinical research efforts concerning investigational treatments for Alzheimer’s disease, will speak on a panel that examines the current state of treatments to combat neurological disorders.


PhRMA  |  From PhRMA

If your company is interested in joining PhRMA, click here to learn more.

Guest Post: Advancing oncology research through clinical trials

PhRMA  |  Blog Post

., medical oncologist and vice president, Global Clinical Oncology, Merck Research Laboratories.

You have reviewed the first 125 results out of 1046. Each page contains 25 results. You're on page 5.

prev 1 2 3 4 5 6 next